Researcher Detects Serious Onalespib Craving

Матеріал з HistoryPedia
Версія від 20:07, 21 травня 2017, створена Knot32gallon (обговореннявнесок) (Створена сторінка: 15�C19 HP-Guar effectively relieves signs and symptoms related to moderate dry eye, with measurable improvements evident in both objective staining and subjec...)

(різн.) ← Попередня версія • Поточна версія (різн.) • Новіша версія → (різн.)
Перейти до: навігація, пошук

15�C19 HP-Guar effectively relieves signs and symptoms related to moderate dry eye, with measurable improvements evident in both objective staining and subjective questionnaire.19 The purpose of this study was to evaluate the efficacy of this lubricant eyedrop solution in improving signs and symptoms of DED, as well as its influence on surface inflammatory markers measured by flow cytometry. Materials and methods Study design This was a single-arm, open-label study of an over-the-counter lubricant eyedrop with active ingredient PEG/PG + HP-Guar (www.ClinicalTrials.gov identifier, NCT00946777). This Institutional Review Board-approved trial was conducted in accordance with the Good Clinical Practice guidelines for the evaluation of medical products and following the tenets of the Declaration of Helsinki. Patients Patients were selected from those being seen at the Faculty Practice Associates at the Department of Ophthalmology, Mount Sinai School of Medicine. Nineteen patients who were diagnosed with mild to moderate DED with typical signs and symptoms were recruited. All patients read, understood, and signed the informed consent form before any examination was obtained. Male as well as female patients who were 18 years of age or older were eligible for the study. Both eyes of each patient were included in the trial. The major inclusion criteria were at least one symptom of dry eye that was graded moderate to severe (rated on a 4-point scale) or clinical evidence of dry eye by Schirmer testing ( were excluded from the study: uncontrolled systemic (ie, diabetes mellitus, rheumatoid arthritis, and other immunologic or autoimmune diseases) or ocular disease (ie, glaucoma or uveitis), dry eye due to seasonal allergic conjunctivitis, contact lens-related selleck compound conjunctivitis or other acute or seasonal diagnoses, monocular and/or legal blindness, history of ocular surgery or trauma within the last 6 months, or participation in an ophthalmic drug or device research trial within 30 days before entry in this study. Materials US Food and Drug Administration-approved over-the-counter lubricant eyedrops were used in this study. The test solution was a PEG/PG-based, HP-Guar�Ccontaining lubricant eyedrop, preserved with POLYQUAD? (Systane Ultra? Lubricant Eye Drops, Alcon Laboratories, Inc., Fort Worth, TX, USA). The product was supplied in its original, unopened container.